Compare NUVL & MGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | MGM |
|---|---|---|
| Founded | 2017 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 9.5B |
| IPO Year | 2021 | 2004 |
| Metric | NUVL | MGM |
|---|---|---|
| Price | $104.15 | $36.55 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 15 |
| Target Price | ★ $134.75 | $42.88 |
| AVG Volume (30 Days) | 543.5K | ★ 3.9M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.76 |
| Revenue | N/A | ★ $9,809,663,000.00 |
| Revenue This Year | N/A | $1.80 |
| Revenue Next Year | $1,235.73 | $1.61 |
| P/E Ratio | ★ N/A | $49.07 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $63.56 | $28.12 |
| 52 Week High | $113.02 | $40.16 |
| Indicator | NUVL | MGM |
|---|---|---|
| Relative Strength Index (RSI) | 54.55 | 48.65 |
| Support Level | $97.63 | $35.82 |
| Resistance Level | $107.08 | $37.94 |
| Average True Range (ATR) | 3.66 | 1.28 |
| MACD | 0.56 | -0.05 |
| Stochastic Oscillator | 72.02 | 28.90 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
MGM Resorts is the largest resort operator on the Las Vegas Strip with 37,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Park MGM, Luxor, New York-New York, and Bellagio. The Strip contributed approximately 56% of total EBITDAR in 2025. MGM also owns US regional assets, which represented a low 20s share of 2025 EBITDAR (MGM's Macao EBITDAR was 23% of the total in 2025). MGM's US sports and i-gaming operations are currently a high-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM China casinos with a second property that opened on the Cotai Strip in early 2018. We estimate MGM will open a resort in Japan in 2030.